Immuno-Oncology | Specialty

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

PD-L1 Expression Remains Primary Guide for NSCLC Treatment Selection in the Absence of Targetable Mutations

August 5th 2024

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

FDA Approves Expanded Indication for Dostarlimab Plus Chemo in Primary Advanced or Recurrent Endometrial Cancer

August 1st 2024

The FDA has approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent endometrial cancer.

Pembrolizumab Plus Chemo Elicits Responses in Head and Neck Squamous Cell Carcinoma

July 27th 2024

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Pembrolizumab Plus Enfortumab Vedotin Earns CHMP Recommendation in Frontline Metastatic Urothelial Carcinoma

July 26th 2024

The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition

July 18th 2024

The addition of nivolumab to tivozanib did not improve PFS in advanced metastatic renal cell carcinoma following prior immune checkpoint inhibition

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

July 16th 2024

Adjuvant nivolumab plus ipilimumab significantly improved 3-year DMFS rates compared with historical controls in patients with high-risk uveal melanoma.

Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies

July 15th 2024

The addition of ipilimumab to cabozantinib plus nivolumab was safe and showed notable efficacy in patients with rare genitourinary cancers.

First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC

July 11th 2024

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Nivolumab/Ipilimumab Yields Responses in Ovarian Clear Cell Carcinoma

July 10th 2024

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC

July 10th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

Dr Philip on the Development of T-Cell Dysfunction in Liver Cancer and Melanoma Cell Models

July 9th 2024

Mary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.

Dr Leidner on the Investigation of TCR-Engineered T-Cell Immunotherapy in Solid Tumors

July 9th 2024

Rom S. Leidner, MD, discusses the investigation of T-cell receptor–engineered T-cell immunotherapy for select patients with solid tumors.

Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors

July 9th 2024

Sarwish Rafiq, PhD, discusses how engineering metabolically fit, memory rich CAR T-cells may address barriers to CAR T-cell efficacy in solid tumors.

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 8th 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Tiragolumab Plus Atezolizumab/Chemo Misses Survival End Points in Metastatic Nonsquamous NSCLC

July 8th 2024

First-line tiragolumab plus atezolizumab and chemotherapy failed to improve survival in advanced nonsquamous non–small cell lung cancer.